Veeva Systems Inc. (VEEV) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Veeva Systems Inc. (VEEV) Healthcare & Pipeline Overview

Veeva Systems Inc. delivers cloud-based software solutions for the life sciences industry, offering a suite of CRM, data, and content management applications. With a focus on regulatory compliance and operational efficiency, Veeva serves pharmaceutical, biotechnology, and healthcare companies globally, positioning itself as a key technology partner in the sector.

What Is the Investment Thesis for VEEV?

Veeva Systems Inc. presents a notable research candidate within the healthcare information services sector. With a market capitalization of $42.8B and a P/E ratio of 42.03, Veeva demonstrates strong financial performance. A gross margin of 75.5% and a profit margin of 28.4% highlight the company's operational efficiency and profitability. Key growth catalysts include the expansion of Veeva Vault into new therapeutic areas and the increasing adoption of Veeva Commercial Cloud solutions by pharmaceutical and biotechnology companies. The company's focus on regulatory compliance and data management within the life sciences industry positions it favorably amid increasing regulatory scrutiny. However, potential risks include competition from established players and the potential for slower growth in mature markets. The company's beta of 1.10 indicates moderate volatility relative to the market.

Based on FMP financials and quantitative analysis

VEEV Key Highlights

Market capitalization of $42.8B reflects strong investor confidence in Veeva's market position and growth potential.

• P/E ratio of 42.03 indicates a premium valuation, reflecting expectations of continued earnings growth.
• Gross margin of 75.5% demonstrates Veeva's pricing power and efficient cost management in its software and services offerings.
• Profit margin of 28.4% underscores the company's ability to convert revenue into profit, showcasing operational excellence.
• Veeva's focus on cloud-based solutions aligns with the increasing demand for scalable and secure data management in the life sciences industry.

Who Are VEEV's Competitors?

VEEV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VEEV's Key Strengths?

Dominant market position in cloud-based solutions for the life sciences industry.

• Comprehensive suite of products and services covering various functional areas.
• Strong customer relationships and high customer retention rates.
• Experienced management team and a culture of innovation.

What Are VEEV's Weaknesses?

Reliance on the life sciences industry, making it vulnerable to industry-specific downturns.

• Relatively high pricing compared to some competitors.
• Limited presence in certain emerging markets.
• Potential for slower growth in mature markets.

What Could Drive VEEV Stock Higher?

Continued expansion of Veeva Vault into new therapeutic areas.

• Increasing adoption of Veeva Commercial Cloud solutions by pharmaceutical and biotechnology companies.
• Potential strategic partnerships and acquisitions to expand product portfolio and market reach.
• Global expansion into emerging markets, such as China and India.
• Development of AI-powered solutions for drug discovery and clinical trial optimization.

What Are the Key Risks for VEEV?

Rich valuation — a P/E of 42.03 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Increasing competition from established players and new entrants in the cloud-based solutions market.
• Evolving regulatory landscape and compliance requirements in the life sciences industry.
• Potential for data breaches and security vulnerabilities in Veeva's cloud infrastructure.
• Economic downturns and reduced healthcare spending impacting demand for Veeva's solutions.
• Dependence on key personnel, including CEO Peter Gassner.

What Are the Growth Opportunities for VEEV?

• Expansion of Veeva Vault into New Therapeutic Areas: Veeva has the opportunity to expand the Veeva Vault platform into new therapeutic areas beyond its current focus. This includes areas such as oncology, cardiovascular diseases, and rare diseases. The market for cloud-based solutions in these therapeutic areas is estimated to be $5 billion by 2028, offering significant growth potential for Veeva. By tailoring Veeva Vault to meet the specific needs of these areas, Veeva can attract new customers and increase its market share.
• Increasing Adoption of Veeva Commercial Cloud: The increasing adoption of Veeva Commercial Cloud solutions by pharmaceutical and biotechnology companies presents a significant growth opportunity. The global market for CRM and commercial solutions in the life sciences industry is projected to reach $12 billion by 2027. Veeva can capitalize on this trend by enhancing its Commercial Cloud offerings with advanced analytics and AI-powered capabilities, attracting more customers seeking to improve their sales and marketing effectiveness.
• Strategic Partnerships and Acquisitions: Veeva can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. This includes partnering with data analytics companies, AI solution providers, and other technology vendors to integrate their capabilities into Veeva's platform. The market for strategic partnerships and acquisitions in the healthcare IT sector is estimated to be $8 billion by 2026. By carefully selecting partners and acquisition targets, Veeva can accelerate its growth and strengthen its competitive position.
• Global Expansion into Emerging Markets: Veeva has the opportunity to expand its presence in emerging markets, such as China, India, and Brazil. These markets are experiencing rapid growth in the life sciences industry, driven by increasing healthcare spending and a growing demand for advanced technologies. The market for cloud-based solutions in these emerging markets is projected to reach $4 billion by 2028. By establishing a strong presence in these markets, Veeva can tap into new revenue streams and diversify its geographic footprint.
• Development of AI-Powered Solutions: Veeva can leverage artificial intelligence (AI) and machine learning (ML) to develop innovative solutions that address the evolving needs of the life sciences industry. This includes AI-powered analytics for drug discovery, clinical trial optimization, and personalized medicine. The market for AI in healthcare is projected to reach $45 billion by 2027. By investing in AI research and development, Veeva can create new revenue streams and differentiate itself from competitors.

What Are VEEV's Competitive Advantages?

• High switching costs due to the mission-critical nature of Veeva's solutions.
• Strong brand reputation and industry expertise.
• Extensive customer network and data assets.
• Proprietary technology and intellectual property.

What Does VEEV Do?

Veeva Systems Inc., founded in 2007 and headquartered in Pleasanton, California, provides cloud-based software solutions specifically designed for the life sciences industry. Originally named Verticals onDemand, Inc., the company rebranded as Veeva Systems Inc. in April 2009, signaling its dedicated focus on the vertical market. Veeva's core offering is the Veeva Commercial Cloud, a comprehensive suite of software, data, and analytics solutions. This includes Veeva CRM and Veeva Medical CRM for customer relationship management, Veeva CLM for closed-loop marketing, Veeva Nitro for data warehousing, Veeva OpenData for healthcare professional data, Veeva Link for key opinion leader insights, Veeva Network for customer master data management, Veeva Crossix for marketing analytics, Veeva Data Cloud, and MyVeeva for Patients. Additionally, Veeva offers Veeva Vault, a cloud-based enterprise content and data management application that manages commercial functions, including sales and marketing, and medical content and communications, as well as research and development functions, such as clinical, regulatory, quality, and safety. Veeva serves a global clientele across North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company also provides professional and support services, including implementation, deployment planning, project management, requirements analysis, solution design, configuration, systems environment management, and technical consulting services.

What Products and Services Does VEEV Offer?

• Provides cloud-based software solutions for the life sciences industry.
• Offers Veeva Commercial Cloud, a suite of CRM, data, and analytics solutions.
• Provides Veeva Vault, a cloud-based enterprise content and data management application.
• Supports commercial functions, including sales and marketing, and medical content and communications.
• Supports research and development functions, such as clinical, regulatory, quality, and safety.
• Offers professional and support services, including implementation and deployment planning.
• Provides ongoing managed services, including outsourced systems administration.

How Does VEEV Make Money?

• Subscription-based revenue from Veeva Commercial Cloud and Veeva Vault.
• Professional services revenue from implementation, deployment, and consulting services.
• Support services revenue from ongoing maintenance and support.
• Data and analytics revenue from Veeva OpenData, Veeva Link, and Veeva Crossix.

What Industry Does VEEV Operate In?

Veeva Systems Inc. operates within the healthcare information services sector, which is experiencing robust growth driven by the increasing adoption of digital technologies in the life sciences industry. The market is characterized by stringent regulatory requirements, increasing data volumes, and a growing need for efficient data management solutions. Veeva competes with established players and niche providers, differentiating itself through its comprehensive suite of cloud-based solutions and its deep industry expertise. The global healthcare IT market is projected to reach $390 billion by 2026, presenting significant growth opportunities for Veeva.

Who Are VEEV's Key Customers?

• Pharmaceutical companies
• Biotechnology companies
• Medical device companies
• Contract research organizations (CROs)

Over the past six months, Veeva Systems Inc. insiders filed 15 SEC Form 4 transactions — 8 sales and 7 purchases. On net that is roughly 235K shares disposed (about $0), a signal worth weighing alongside the fundamentals.

Veeva Systems Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 7.3% above estimates on average.

Veeva Systems Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 18.09 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Veeva Systems Inc. stands at 13.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.3%, showing how much profit it generates from its asset base. VEEV trades at a trailing price-to-earnings ratio of 42.03, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.74 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.9%, the inverse of the P/E and a quick read on earnings relative to price.

Veeva Systems Inc. (VEEV) Valuation Context

Valued at $42.8B, VEEV is classified as a large-cap stock. Analyst price targets span from $165.00 to $330.00, with a consensus of $290.50. At the current price of $263.67, that implies approximately 10% upside potential. Relative to its peer group, VEEV's quantitative score of 90/100 is above the peer average of 74/100.

VEEV Revenue & Earnings Trend

In Q2 FY2027, VEEV generated $928.0M in top-line revenue, marking a sequential increase of 5.1%. The company recorded net income of $273.4M, with diluted EPS of $1.66. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, VEEV averaged $1.52 in diluted EPS.

Company Profile

Veeva Systems Inc. operates in the Software - Application industry within the Technology sector. It is headquartered in Pleasanton, US. The company is led by CEO Peter Gassner. VEEV has traded publicly since 2013.

VEEV Financials

VEEV Latest News

VEEV Analyst Consensus

VEEV MoonshotScore

Latest Veeva Systems Inc. Analysis

VEEV Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources